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Objectives: This study investigated the fluoroquinolone-resistant mechanism of
56 clinical cases of A baumannii infection from 23 non-tertiary hospitals,
collected between 2004 and 2006.
Methods: Susceptibility testing was performed by broth microdilution and
Epsilometer test. Analyses of quinolone resistance-determining region (QRDR)
were done by sequencing. The activity of the efflux pump was measured using
inhibitors.
Results: The sequences from selected 56 isolates were divided into seven groups
(IeVII) on the basis of mutations in gyrA (S83L), parC (S80L, S80W and S84K) and
gyrB (containing the novel mutations E679D, D644Y and A677V). The 27 isolates
with triple mutations in gyrA, gyrB and parC (groups IVeVII) showed higher levels
of resistance to ciprofloxacin (minimal inhibitory concentration [MIC] of 16e
256 mg/mL) than the 26 isolates with double mutations in gyrA and parC (groups II
and III, MIC of 8e64 mg/mL; p< 0.05). Alterations in the efflux pump were
observed in four isolates with the parC S80L mutation (group II) or E84K mutation
(group VII), but no effect was observed in an isolate with the parC S80 W
mutation (group III).
Conclusion: These results suggest that triple mutations in clinical isolates of A
baumannii contribute to the development of high levels of resistance to fluo-
roquinolones and that mutations in parC S80L or E84K (groups II and VII) may
contribute to alterations in efflux pump activity in A baumannii.1. Introduction
Over the past three decades, Acinetobacter baumannii
has emerged as an important nosocomial pathogenibuted under the terms o
y-nc/3.0) which permits un
is properly cited.
ase Control and Preventionworldwide [1]. Certain strains of A baumannii are now
resistant to many common antimicrobial agents,
including fluoroquinolone, and multidrug resistance is
often responsible for the failure of antibiotic therapyf the Creative Commons Attribution Non-Commercial License
restricted non-commercial use, distribution, and reproduction in
. Published by Elsevier Korea LLC. All rights reserved.
Fluoroquinolone resistance in A baumannii 165[2,3]. Resistance to fluoroquinolone is mediated
primarily through spontaneous mutations of genes in the
quinolone resistance-determining region (QRDR),
namely, DNA gyrase and topoisomerase IV. Alterations
in the drug target due to modifications in the genes for
DNA gyrase subunit A (gyrA) or topoisomerase IV
subunit C (parC) have been associated with high levels
of resistance to fluoroquinolones [4e6]. A secondary
cause of resistance to fluoroquinolone is alterations in
the efflux pump that lead to active efflux of the drug.
Efflux pumps typically have broad substrate specificity
that contributes to resistance against multiple unrelated
classes of drug, including aminoglycosides, tetracycline,
fluoroquinolones, trimethoprim and chloramphenicol
[7,8].
DNA gyrase is the target of a number of quinolones,
including ciprofloxacin, levofloxacin, gemifloxacin and
gatifloxacin [9,10]. Quinolones produce bacteriostatic
activity by binding rapidly to the enzymeeDNA
complex, probably before DNA cleavage occurs,
thereby blocking DNA replication and transcription. The
quinolones can bind to the complexes even with muta-
tions in the genes for DNA gyrase or topoisomerase IV
that result in an inability to cleave DNA [11,12]. The
protein product of gyrB consists of two domains:
a 43-kDa N-terminal domain containing a site for ATP
binding and hydrolysis that is thought to act as a DNA
clamp; and a 47-kDa C-terminal domain that is thought
to play a role in strand passage and interactions with
gyrA and DNA. GyrA and GyrB form a functional
A2B2 tetramer [11,12].
Many fluoroquinolone-resistant clinical isolates of A
baumannii have emerged rapidly in South Korea
[13,14]. There are, however, few studies on the resis-
tance to fluoroquinolone and the prevalence of muta-
tions in the genes for DNA gyrase and topoisomerase IV
in clinical isolates of A baumannii from the South
Korean population. The role of the A baumannii efflux
pump on fluoroquinolone resistance has not been fully
investigated. Therefore, the aim of this study was to
investigate the mechanisms of resistance to fluo-
roquinolone in clinical isolates of A baumannii from
non-tertiary hospitals in South Korea. Specifically, we
assessed: (i) the presence of mutations in the gyrA, gyrB
and parC genes and the effect of different mutations on
resistance to fluoroquinolone; and (ii) the presence of
alterations in the efflux pump mechanism and their
effects on resistance to fluoroquinolone.2. Method and Materials
2.1. Bacterial strains and growth conditions
Fifty-six nonrepetitive clinical isolates of
fluoroquinolone-resistant A baumannii from non-tertiary
hospitals, collected between 2004 and 2006, wereselected for this study. The A baumannii isolates were
compared with the reference Escherichia coli ATCC
25922 strain (American Type Culture Collection,
Manassas, VA, USA) for minimal inhibitory concentra-
tion (MIC) analysis and with the A baumannii ATCC
19606 strain forQRDRanalysis. The clinical isolateswere
propagated at 37C in nutrient broth or agar. The clinical
isolates and reference bacteria were propagated aerobi-
cally at 37C in Luria-Bertani (LB) broth until they
reached mid-log growth. The clinical isolates were iden-
tified using the Vitek II automatic system (bioMerieux,
Carcy-I’Etole, France).
2.2. Antimicrobial susceptibility testing
The MICs for ciprofloxacin, gemifloxacin, levo-
floxacin, norfloxacin and gatifloxacin were determined
by Epsilometer test (Etest, AB BIODISK, Piscataway,
NJ, USA) and the broth microdilution method,
following the manufacturer’s instructions, which were
based on the guidelines of the Clinical and Laboratory
Standards Institute [15]. The MIC for each drug was
determined by a serial dilution of test compounds
(Sigma-Aldrich, St Louis, MO, USA) in Mueller-Hinton
broth (Becton Dickinson & Co., Sparks, MD, USA) with
the bacteria at a density of 5 105 colony-forming
units/mL. Plates were incubated at 37C for 20 hours
and growth was then assayed by measuring the optical
density at 595 nm.
2.3. Quinolone resistance-determining region
analysis
The QRDR analysis was conducted using the control
sequence for gyrA (DQ270238), gyrB (CU468230) and
parC (X95816). The primers were used to amplify the
DNA and for sequencing (Table 1). Genomic DNA was
extracted from the prepared isolates using the Qiagen
genomic DNA purification kit (Qiagen, Hilden,
Germany). Universal polymerase chain reaction (PCR)
was used to confirm that the DNA samples contained the
fluoroquinolone resistance genes (Table 1). A 1:100
dilution of DNA in Tris-EDTA (TE) buffer was used
in the PCR. DNA amplification was carried out in
a GeneAmp PCR system 2400 (Applied Biosystems,
Foster City, CA, USA) instrument with initial denatur-
ation at 95C for 2 minutes followed by 30 cycles of
amplification (denaturation at 95C for 30 seconds, then
annealing for 30 seconds at primer set-specific temper-
atures, and extension at 72C for 1 minute), ending with
a final extension at 72C for 5 minutes. The PCR
products were stained with ethidium bromide and pho-
tographed with ultraviolet illumination.
2.4. Treatment of efflux pump inhibitors
The growth inhibition assays were conducted as
described previously [16], using efflux pump inhibitors
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166 S. Park, et al(EPIs) including carbonyl cyanide 3-
chlorophenylhydrazone (CCCP), 1-(1-naphthylmethyl)-
piperazine (NMP), phenyl-arginine-b-naphthylamide
(PAbN), reserpine and verapamil (Sigma-Aldrich, St.
Louis, MO, USA). The antimicrobial susceptibility test
was conducted with levofloxacin, ciprofloxacin, gemi-
floxacin and norfloxacin in the presence or absence of
each EPI at the following concentrations: 25 mg/mL
PAbN, 10 mg/mL CCCP, 50 mg/mL NMP, 50 mg/mL
reserpine and 100 mg/mL verapamil. Each EPI was
tested at least three times.
2.5. Computer analysis of sequence data
Nucleotide sequence data were analyzed using the
Clustal W software program (European Bioinformatics
Institute, Cambridge, UK) [17]. The amino acid
sequences were analyzed at the National Center for
Biotechnology Information (www.ncbi.nlm.nih.gov/
BLAST). The GenBank and protein databases were
screened for sequence similarity. The primer sets were
designed using the sequences of the genes for DNA
gyrase (gyrA and gyrB) and topoisomerase IV (parC )
from the 56 clinical isolates of A baumannii, using the
PrimerSelect program from the DNA Lasergene analysis
software package (DNASTAR, Inc., Madison, WI,
USA).
2.6. Statistical analysis
Statistical testing to determine differences in anti-
microbial resistance was conducted using SPSS for MS
Windows (version 11.5; SPSS, Inc., Chicago, IL, USA).
Continuous variables were compared using Student’s t
test, and categorical variables were compared using
Fisher’s exact test or chi-squared analysis. A p value of
<0.05 was considered statistically significant.3. Results
3.1. Novel gyrB mutant sites and amino acid
substitutions within QRDRs
The 56 clinical isolates were identified from the
QRDR analysis. The isolates were divided into seven
groups according to the amino acid substitutions in the
protein products of gyrA, gyrB and parC (Table 2). A
mutation encoding Ser83/ Leu was detected in the
QRDR of gyrA in all of the A baumannii isolates
studied. Three different mutations were observed in the
QRDR of gyrB encoding Glu479/Asp (3.6%),
Asp644/ Tyr (12.5%) and Ala677/Val (37.5%) in
30 (53.6%) A baumannii isolates. Fifty-three of the 56 A
baumannii isolates (94.6%) showed a single mutation in
parC encoding Ser80/ Leu (30; 53.6%), Ser80/ Trp
(2; 3.6%) and Glu84/ Lys (21; 37.5%). Overall, 27
(48.2%) of the 56 fluoroquinolone -resistant A bau-
mannii isolates showed mutations in the QRDR of gyrA,
gyrB and parC.
Table 2. Mutations in the GyrA, GyrB and ParC subunits in A baumannii isolates, and the MIC for different fluoroquinolone in groups of mutant isolates
Mutation
groups
No. of
isolates Agent
No. of isolates with MIC (mg/mL) GyrA GyrB ParC
1 2 4 8 16 32 64 128 >256 S83 (tca) E479 (gaa) D644 (gat) A677 (gcg) S80 (tcg) E84 (gaa)
I 3 Ciprofloxacin 1 2 L(tta) Y(tat)
Gatifloxacin 3
Gemifloxacin 3
Levofloxacin 1 2
II 25 Ciprofloxacin 2 1 20 2 L(tta) L(ttg)
Gatifloxacin 1 2 16 6
Gemifloxacin 2 3 14 5 1
Levofloxacin 2 17 4 2
III 1 Ciprofloxacin 1
Gatifloxacin 1 L(tta) W(tgg)
Gemifloxacin 1
Levofloxacin 1
IV 1 Ciprofloxacin 1 L(tta) D(gat) L(ttg)
Gatifloxacin 1
Gemifloxacin 1
Levofloxacin 1
V 1 Ciprofloxacin 1 L(tta) D(gat) W(tgg)
Gatifloxacin 1
Gemifloxacin 1
Levofloxacin 1
VI 4 Ciprofloxacin 1 2 1 L(tta) Y(tat) L(ttg)
Gatifloxacin 2 1 1
Gemifloxacin 1 3
Levofloxacin 2 1 1
VII 21 Ciprofloxacin 11 9 L(tta) V(gtg) K(aaa)
Gatifloxacin 18 2 1
Gemifloxacin 4 9 8
Levofloxacin 5 16
AZ alanine, DZ aspartic acid, EZ glutamic acid, KZ lysine, LZ leucine, MICZminimal inhibitory concentration, SZ serine, VZ valine, WZ tryptophan, YZ tyrosine.
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168 S. Park, et al3.2. MIC for fluoroquinolone in the QRDR
mutants
Group I mutants had mutations in gyrA and gyrB and
showed resistance to four fluoroquinolones, but their
MIC was 4 mg/mL. Group II and III mutants had
double mutations in gyrA and parC and showed resis-
tance to ciprofloxacin (MIC 8e64 mg/mL), gatifloxacin
(MIC 1e8 mg/mL), gemifloxacin (MIC 2e32 mg/mL)
and levofloxacin (MIC 2e16 mg/mL). Groups IV, V, VI
and VII mutants had triple mutations in gyrA, gyrB
and parC. They were resistant to ciprofloxacin (MIC
16e256 mg/mL), gatifloxacin (MIC 4e32 mg/mL),
gemifloxacin (MIC 4e32 mg/mL) and levofloxacin
(MIC 4e32 mg/mL), p< 0.05). Overall, isolates with
triple mutations of gyrA, gyrB and parC had a higher
level of resistance to fluoroquinolone than isolates with
double mutations of gyrA and parC (p< 0.05).
3.3. Efflux pump analysis
To evaluate the contribution of the efflux pump to the
fluoroquinolone-resistant phenotype of five isolates fromTable 3. The MIC for fluoroquinolone in the absence or presen
Group Isolate þ EPI
MIC (
NOR CIP
II 5733 alone >256 >32
þ CCCP >256 >32
þPAbN >256 >32
þ NMP >256 >32
þ reserpine >256 >32
þ verapamil >256 >32
II 5A38 alone >256 >32
þ CCCP >256 >32
þ PAbN >256 >32
þ NMP >256 >32
þ reserpine >256 >32
þ verapamil >256 >32
III 6018 alone >256 >32
þCCCP >256 >32
þPAbN >256 >32
þNMP >256 >32
þReserpine >256 >32
þVerapamil >256 >32
VII 6A69 alone >256 >32
þ CCCP >256 >32
þ PAbN >256 >32
þ NMP >256 >32
þ reserpine >256 >32
þ verapamil >256 >32
VII 6A80 alone >256 >32
þ CCCP >256 >32
þ PAbN >256 >32
þ NMP >256 >32
þ reserpine >256 >32
þ verapamil >256 >32
*Average MIC values were determined by Etest at least three times (standard d
CCCPZ carbonyl cyanide 3-chlorophenylhydrazone, CIPZ ciprofloxacin, E
MICZminimal inhibitory concentration, NMPZ 1-(1-naphthylmethyl)-piperazdifferent QRDRmutation groups, we compared the MIC
for each fluoroquinolone in the presence or absence of
CCCP, PAbN, NMP, reserpine and verapamil (Table 3).
For four isolates (5733, 5A38, 6A69 and 6A80), the four
EPIs PAbN, NMP, reserpine and verapamil significantly
reduced the MIC (by two- to eightfold) for levofloxacin.
These four isolates belonged to groups II (GyrA S83L;
ParC S80L) and VII (GyrA S83L; GyrB A677V; ParC
E84K). They showed a high level of resistance to lev-
ofloxacin (MIC >32 mg/mL). The remaining isolate,
which was not affected by the EPIs, belonged to group
III (GyrA S83L; ParC S80W) and showed less resis-
tance to levofloxacin (8 mg/mL) than the other four
isolates.4. Discussion
The purpose of this study was to investigate mecha-
nisms of resistance to fluoroquinolone in clinical isolates
of A baumannii. The results of the present studyce of EPIs*
mg/mL) QRDR mutation
GEM LEV GyrA GyrB ParC
25.3 >32 S83L S80L
12.7 4.0
8.0 4.0
19.3 6.0
24.0 4.0
15.3 12.0
54.3 >32 S83L S80L
11.0 >32
14.7 4.0
49.3 6.0
8.0 6.0
5.5 4.0
16.0 8.0 S83L S80W
13.3 8.0
15.3 8.0
13.3 8.0
36.7 8.0
38.7 >32
13.0 >32 S83L A677V E84K
7.3 >32
6.0 4.0
10.3 6.0
11.3 6.0
10.0 12.0
7.0 >32 S83L A677V E84 K
6.0 >32
3.7 4.0
7.7 6.0
7.3 4.0
3.3 6.0
eviation 0.2e12).
PIZ efflux pump inhibitor, GEMZ gemifloxacin, LEVZ levofloxacin,
ine, NORZ norfloxacin, PAbNZ phenylarginine-b-naphthylamide.
Fluoroquinolone resistance in A baumannii 169correspond well with those of earlier studies, which have
shown that the most common mechanism of resistance
to fluoroquinolone in A baumannii involves alterations
in the genes that encode subunits of the quinolone
targets DNA GryA (S83L, G81V or C and A84P) and
ParC (S80L or W, E84K and G78C) [4e6]. Mutations
in the GyrA and GyrB subunits of DNA gyrase and the
ParC and ParE subunits of topoisomerase IV play
a major role in conferring a high level of resistance to
fluoroquinolone in other Gram-negative bacteria, such
as E coli and Pseudomonas aeruginosa [18,19]. The
outer membrane of A baumannii has been associated
with intrinsic antimicrobial resistance resulting from the
over-expression of the adeABC and adeFGH efflux
pump genes [20,21]. These findings indicate that active
efflux is involved in both intrinsic and acquired resis-
tance to fluoroquinolones. The outer membrane of P
aeruginosa shows little permeability to small hydro-
phobic molecules, which may account for the intrinsic
resistance of P aeruginosa to quinolones. In fact, the
outer membrane of P aeruginosa is 10- to 100-fold less
permeable to antimicrobial agents than the outer
membrane of E coli [22]. Additional efflux pumps
associated with resistance to fluoroquinolone have also
been characterized in E coli and other Gram-negative
bacteria [22,23].
In the present study, clinical isolates of A baumannii
with identical mutations in the QRDR of gyrA, gyrB and
parC genes showed very different levels of resistance to
fluoroquinolones.
It is controversial whether the efflux pump has
a contributory effect on the resistance of A baumannii to
fluoroquinolone [2,24]. Although we cannot exclude the
presence of QRDR mutations outside of the region that
we sequenced, our results suggest that the differences in
resistance that were observed were due to differences in
the active efflux of fluoroquinolone.
The effects of CCCP and PAßNethat primarily
inhibit RND-family efflux pumpseand reserpine and
verapamilethat primarily inhibit non-RND-family efflux
pumpseon antimicrobial susceptibility have been
examined previously [16,25]. Although these inhibitors
have preferences for certain classes of pumps, their
activity cannot be assumed to be exclusive to one class.
The present study showed that the EPIs also reduced the
MIC of fluoroquinolone, but only in isolates with clon-
ally related parC mutations (S80L in group II and E84K
in group VII). It did not have this effect in the S80W
parC mutation (group III).
In conclusion, although a single mutation in DNA
gyrase is sufficient for resistance to fluoroquinolone, the
accumulation of triple mutations in the QRDR regions
of the gyrA, gyrB and ParC genes is expected to
significantly contribute to high-level fluoroquinolone
resistance. We have demonstrated a role for the efflux
pump in conferring resistance to fluoroquinolone in
clinical isolates that carry S80L or E84K mutations inparC. Further studies are needed to elucidate the role of
over-expression of the efflux pump on fluoroquinolone
resistance.Acknowledgements
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